Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.
Evangeline Samuel, Gabrielle Lie, Adithya Balasubramanian, Alison Hiong, Yeojeong So, Mark Voskoboynik, Maggie Moore, Mark Shackleton, Andrew Haydon, Tom John, Paul LR Mitchell, Ben Markman, Peter Briggs, Sagun Parakh
Clin Lung Cancer | Published : 2021
BACKGROUND: The impact of radiotherapy (RT) on the efficacy and toxicity of immune checkpoint inhibitors (ICIs) in patients with metastatic non-small-cell lung cancer (NSCLC) is unclear. MATERIALS AND METHODS: We identified patients with metastatic NSCLC treated with the anti-programmed death 1 antibodies nivolumab or pembrolizumab between January 2016 and May 2019 at 3 tertiary centers, who were also treated with palliative RT either during or within 3 months of starting anti-programmed death 1 treatment. Patient demographics, tumor characteristics, and treatment history were collected. Response rates, progression-free survival (PFS), and overall survival (OS) were analyzed and correlated w..View full abstract